RASCO PHARMA
Pharmaceutical manufacturer · Lahore · Pakistan
Lahore pharmaceutical manufacturer operating since 2004 with generic medicines, quality-control infrastructure and multiple dosage forms.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer
- Address
- 5.5 KM, Near Ali Raza Abad, Holiday Park, Plot No. 27, Raiwind Road, Lahore, Pakistan
- Website
- rascopharma.com ↗
- Phone
- +92 42 35230774-5
- info@rascopharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| A.Z Ko | Azithromycin | 250 mg | Tablet | 10's | 040180 | PKR 525.25 | PKR 52.53/tablet | 12% above median |
| A.Z Ko | Azithromycin | 500 mg | Tablet | 6's | 107068 | PKR 412.69 | PKR 68.78/tablet | 19% below median |
| AZ-Ko | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 041630 | PKR 329.13 | PKR 21.94/mL | Near median |
| AZ-Ko | Azithromycin | 250 mg | Capsule | 1x6's | 050202 | PKR 247.84 | PKR 41.31/capsule | 17% below median |
| AZ-Ko | Azithromycin | 250 mg | Capsule | 10's | 050202 | PKR 508.66 | PKR 50.87/capsule | Near median |
| B-Lex | Cephalexin | 125 mg/5 mL | Suspension | 60ml | 038951 | PKR 131.37 | PKR 2.19/mL | 18% above median |
| B-Lex | Cephalexin | 250 mg/5 mL | Suspension | 60ml | 038952 | PKR 227.11 | PKR 3.79/mL | 18% above median |
| B-Lex | Cephalexin | 500 mg | Capsule | 12's | 038961 | PKR 325.45 | PKR 27.12/capsule | 12% below median |
| B-Lex | Cephalexin | 250 mg | Capsule | 12's | 050655 | PKR 164.79 | PKR 13.73/capsule | 12% below median |
| Bactiphin | Ceftriaxone | 250 mg | Injection | 1Vial | 050657 | PKR 201.47 | PKR 201.47/vial/unit | Near median |
| Bactiphin | Ceftriaxone | 500 mg | Injection | 1Vial | 050658 | PKR 350.17 | PKR 350.17/vial/unit | 8% above median |
| Bactiphin | Ceftriaxone | 1 g | Injection | 1Vial | 050659 | PKR 640.29 | PKR 640.29/vial/unit | 7% above median |
| Cip-Rx | Ciprofloxacin | 250 mg | Tablet | 1x10's | 040156 | PKR 259.32 | PKR 25.93/tablet | Near median |
| Cip-Rx | Ciprofloxacin | 500 mg | Tablet | 1x10's | 040157 | PKR 535.55 | PKR 53.56/tablet | 25% above median |
| Cip-Rx | Ciprofloxacin | 200 mg | IV infusion | 100ml x1's | 078929 | PKR 199.47 | PKR 1.99/mL | 12% below median |
| Ixalt | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 063157 | PKR 638.30 | PKR 39.89/tablet | Near median |
| Ixalt | Artemether | 80 mg | Injection | 6's | 080018 | PKR 1,196.82 | PKR 199.47/vial/unit | Near median |
| Levofloxa-250 | Levofloxacin | 250 mg | Tablet | 1x10's | 040170 | PKR 498.68 | PKR 49.87/tablet | Near median |
| Levofloxa-500 | Levofloxacin | 500 mg | Tablet | 10's | 041626 | PKR 829.80 | PKR 82.98/tablet | Near median |
| Moxiline | Moxifloxacin | 400 mg | Tablet | 1X5's | 059698 | PKR 978.41 | PKR 195.68/tablet | 6% above median |
| Pharmatran | Sulfamethoxazole + Trimethoprim | 200 mg + 40 mg / 5 mL | Suspension | 50ml | 032406 | PKR 46.76 | PKR 0.94/mL | 37% above median |
| Pharmatran DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100's Jar | 032417 | PKR 493.95 | — | No comparator |
| Pharmatran DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 10 x 10's | 032417 | PKR 969.34 | PKR 9.69/tablet | Near median |
| Pharmatran Paediatric | Sulfamethoxazole + Trimethoprim | 40 mg/5 mL + 200 mg/5 mL | Suspension | 400ml | 032406 | PKR 153.75 | PKR 0.38/mL | 11% below median |
| Ras-Q | Hydroxychloroquine | 200 mg | Tablet | 50.s | 101926 | PKR 830.97 | — | No comparator |
| Ras-Q | Hydroxychloroquine | 200 mg | Tablet | 30.s | 101926 | PKR 498.59 | — | No comparator |
| Rasco Pharmafin | Cefotaxime | 250 mg | Injection | 1Vial | 050662 | PKR 110.89 | PKR 110.89/vial/unit | 5% above median |
| Rasco Pharmafin | Cefotaxime | 500 mg | Injection | 1Vial | 050663 | PKR 170.61 | PKR 170.61/vial/unit | 7% above median |
| Rasco Pharmafin | Cefotaxime | 1 g | Injection | 1Vial | 050664 | PKR 306.87 | PKR 306.87/vial/unit | 7% above median |
| Rasco Pharmatran | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 20x10's | 032416 | PKR 623.95 | PKR 3.12/tablet | 43% above median |
| Rasco Pharmatran | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 200's Jar | 032416 | PKR 659.99 | — | No comparator |
| Refspan | Cefixime | 100 mg/5 mL | Suspension | 30ml | 038949 | PKR 330.39 | PKR 11.01/mL | Near median |
| Refspan | Cefixime | 400 mg | Capsule | 5's | 041631 | PKR 592.03 | PKR 118.41/capsule | Near median |
| Resgyl | Metronidazole | 200 mg | Tablet | 500's Jar | 032418 | PKR 1,102.36 | — | No comparator |
| Resgyl | Metronidazole | 200 mg | Tablet | 10x10's | 032418 | PKR 236.56 | PKR 2.37/tablet | 11% above median |
| Resgyl | Metronidazole | 400 mg | Tablet | 250's Jar | 032419 | PKR 804.30 | — | No comparator |
| Resgyl | Metronidazole | 400 mg | Tablet | 10x10's | 032419 | PKR 354.84 | PKR 3.55/tablet | 19% above median |
| Resgyl | Metronidazole | 500 mg/100 mL | IV infusion | 100ml x1's | 078931 | PKR 189.93 | PKR 1.90/mL | Near median |
| Theracid-250 | Clarithromycin | 250 mg | Tablet | 10's | 040177 | PKR 494.35 | PKR 49.44/tablet | Near median |
| Theracid-500 | Clarithromycin | 500 mg | Tablet | 10's | 040178 | PKR 887.64 | PKR 88.76/tablet | 6% above median |
| Voxicin | Doxycycline | 100 mg | Capsule | 5x10's | 067961 | PKR 398.94 | PKR 7.98/capsule | Near median |
| Voxicin | Doxycycline | 100 mg | Capsule | 10x10's | 067961 | PKR 757.98 | PKR 7.58/capsule | Near median |
| Vulamox | Amoxicillin + clavulanic acid | 875 mg + 125 mg | Tablet | 6s | 038947 | PKR 309.22 | PKR 51.54/tablet | Near median |
| Vulamox | Amoxicillin + clavulanic acid | 500 mg + 125 mg | Tablet | 6's | 041055 | PKR 239.36 | PKR 39.89/tablet | Near median |
| Zolinf | Linezolid | 200 mg/100 mL | IV infusion | 100ml x1's | 078930 | PKR 690.16 | PKR 6.90/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.